General eligibility criteria for Greece
Regarding the Medical Technology Products category, products submitted for consideration must have received marketing authorization in Greece between January 1st 2025 and April 30th 2026, inclusive.
Qualitative criteria
Candidate products may belong to any therapeutic category. However, the Awards will be conferred to those products that contribute to improving patients’ quality of life or saving lives, based on the following two criteria:
- What was the degree of innovation demonstrated throughout the scientific development of the product, including its mechanism of action and clinical utility?
- What is the potential contribution of the product to the future advancement of medical science through its introduction into clinical practice?
Only one winner shall be selected in each Award category. However, in the event of a tie between two or more candidates, the Jury reserves the right to designate a second winner under the Hors Prix distinction.
The following factors shall not be taken into consideration in the evaluation process: market size (including the number of cases or product sales), company size, development costs, or any other factors related to product distribution that are beyond the applicant’s control.
Specific eligibility and submission criteria for Greece
Products eligible for consideration in this category must have received certification from a European Notified Body and be commercially available in Greece.
Proposal summary (1 page)
The proposal should begin with a concise summary outlining the product’s principal indications and highlighting the key elements of the nomination.
Rationale and innovation (3 pages)
This section should address the following:
- The background and rationale behind the design and development of the product, including how and why it was developed.
- The key areas in which the product offers advantages over previously available products in the same category, with regard to its technological design, application, method of use, ease of use, reliability, accuracy and effectiveness.
- The use of innovative technologies or techniques in the design and development of the product.
Impact on population health (5 pages)
This section should address the following:
- The anticipated market size and market penetration.
- Comparisons with key competing products.
- The anticipated impact on patients.
- The estimated contribution and benefits to public health.
Conclusions (1 page)
This section is optional. Applicants may, however, wish to provide a concise summary of the product’s key strengths, advantages and added value.
Application summary (1 page)
This section should:
- Provide the reader with a clear overview of the product’s key characteristics relevant to its intended indication and innovative features.
- Include details regarding the product’s regulatory authorisation, including, where applicable, whether the authorisation is granted for a limited period and/or subject to specific conditions.
- State whether the product is currently subject to any safety-related regulatory appeal or review by the European Medicines Agency (EMA).
Submission and formatting requirements
The total length of the nomination dossier for each award category must not exceed 20 A4 pages.
The document should be prepared using:
- 12-point Arial font
- 1.5 line spacing
- 2 cm margins
All supporting documentation and relevant certificates must be submitted electronically together with the awards application online form.
Application fees
For further information regarding the application fee and the benefits associated with your nomination for the “Best Medical Technology Product”, please contact us at info@jpcom.gr or by phone at +30 210 813 2828 or +30 210 813 2366.